The Business Times
business-time-50

Merck

International

Merck to create separate cancer business as Keytruda patent loss looms

Merck plans to reduce its global real estate footprint and optimise its manufacturing network.
Consumer & Healthcare

Merck to cut jobs and costs as demand for Gardasil in China remains weak

Merck’s acquisition would fast track the international launch of the drug in countries outside the US.
Consumer & Healthcare

Merck nears US$10 billion deal for London-based lung therapy firm Verona, FT reports

Merck submitted a nonbinding offer for MoonLake Immunotherapeutics earlier this year, according to the report, which added that the initial approach was rejected but talks could be revived.
Companies & Markets

Merck held talks to buy biotech MoonLake for over US$3 billion: FT

Merck can now integrate vaccine production within its own manufacturing network to supply global markets.
Consumer & Healthcare

China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million

Drugmakers have been racing to come up with pills that could duplicate the effects of Ozempic but would be more convenient to take.
Consumer & Healthcare

Merck snags Chinese obesity drug in nearly US$2 billion deal

The deal with LaNova Medicines bolsters Merck’s push into the promising new field of dual-targeted antibodies.
Consumer & Healthcare

Merck snags Chinese cancer drug for up to US$3.3 billion

Merck now expects total sales of up to US$64.1 billion for the year, US$300 million less than the top end of the guidance the company provided three months ago.
Consumer & Healthcare

Merck narrows sales outlook with Gardasil lagging in China

Merck narrowed expectations for its Life Science business, aiming for annual organic sales growth in a 7-to-9 per cent range from a previously anticipated 7 to 10 per cent.
Consumer & Healthcare

Germany’s Merck open to more M&A for its Life Science division

Merck posted a profit of US$5.5 billion, or US$2.14 per share for its second-quarter results on strong growth of its blockbuster cancer immunotherapy Keytruda.
Companies & Markets

Merck cuts annual profit forecast

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More